Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma”

10 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 10 of 10 results

Not applicableStudy completedNCT02139592
What this trial is testing

Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"

Who this might be right for
Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma
Takeda 292
Not applicableNo Longer AvailableNCT01196208
What this trial is testing

A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001

Who this might be right for
Disease, HodgkinLymphoma, Large-Cell, AnaplasticLymphoma, Non-Hodgkin+1 more
Seagen Inc.
Testing effectiveness (Phase 2)Study completedNCT02939014
What this trial is testing

Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)

Who this might be right for
Hodgkin DiseaseLymphoma, Large-Cell, Anaplastic
Takeda 39
Testing effectiveness (Phase 2)Study completedNCT00117988
What this trial is testing

17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma

Who this might be right for
Anaplastic Large Cell LymphomaRecurrent Adult Hodgkin LymphomaRecurrent Mantle Cell Lymphoma
National Cancer Institute (NCI) 22
Early research (Phase 1)Study completedNCT01950364
What this trial is testing

Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma

Who this might be right for
Hodgkin LymphomaAnaplastic Large-cell Lymphoma
Millennium Pharmaceuticals, Inc. 20
Early research (Phase 1)Looking for participantsNCT06176690
What this trial is testing

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

Who this might be right for
CD30-Positive Diffuse Large B-Cell LymphomaAnaplastic Large Cell Lymphoma, T Cell and Null Cell TypeAnaplastic Large Cell Lymphoma, ALK-Positive+4 more
Baylor College of Medicine 90
Early research (Phase 1)Active Not RecruitingNCT04526834
What this trial is testing

Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma

Who this might be right for
Anaplastic Large Cell LymphomaPeripheral T Cell LymphomaExtranodal NK/T-cell Lymphoma+2 more
Tessa Therapeutics 21
Testing effectiveness (Phase 2)Ended earlyNCT00810576
What this trial is testing

Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
M.D. Anderson Cancer Center 1
Testing effectiveness (Phase 2)Study completedNCT00059995
What this trial is testing

MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma

Who this might be right for
Lymphoma
Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)Ended earlyNCT03947255
What this trial is testing

Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma

Who this might be right for
Hodgkin LymphomaPeripheral T Cell LymphomaAnaplastic Large Cell Lymphoma
Seagen Inc. 12